# Impax Laboratories, LLC clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Impax Laboratories, LLC as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Impax Laboratories, LLC: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/impax-laboratories-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| January 9, 2025 | NCT06765668 | A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Impax Laboratories, LLC | Phase 4 | Recruiting | Parkinson Disease | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06765668) |
| December 7, 2023 | NCT06161220 | A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects | Impax Laboratories, LLC | Phase 1 | Completed | Cardiac Repolarization in Healthy Subjects | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06161220) |
| March 15, 2019 | NCT03877510 | Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor... | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson Disease | 419 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03877510) |
| September 14, 2018 | NCT03670953 | A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson's Disease (Disorder) | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03670953) |
| September 8, 2017 | NCT03275922 | Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE | Impax Laboratories, LLC | Phase 3 | Completed | Migraine | 374 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03275922) |
| January 2, 2017 | NCT03007888 | A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease | Impax Laboratories, LLC | Phase 2 | Completed | Advanced Parkinson's Disease | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03007888) |
| October 22, 2014 | NCT02271503 | A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease | Impax Laboratories, LLC | Phase 2 | Completed | Parkinson's Disease | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02271503) |
| January 31, 2012 | NCT01521663 | Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS) | Impax Laboratories, LLC | Phase 2 | Completed | Restless Legs Syndrome | 159 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01521663) |
| August 8, 2011 | NCT01411137 | Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson's Disease | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01411137) |
| May 26, 2010 | NCT01130493 | A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson's Disease | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01130493) |
| March 31, 2010 | NCT01096186 | An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson's Disease | 617 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01096186) |
| September 11, 2009 | NCT00974974 | A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD). | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson's Disease | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00974974) |
| June 4, 2009 | NCT00914290 | A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis | Impax Laboratories, LLC | Phase 2 | Completed | Spasticity, Multiple Sclerosis | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00914290) |
| April 14, 2009 | NCT00880620 | A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease | Impax Laboratories, LLC | Phase 3 | Completed | Parkinson's Disease | 381 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00880620) |
| March 26, 2009 | NCT00869791 | A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-Levodopa | Impax Laboratories, LLC | Phase 2 | Completed | Parkinson's Disease | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00869791) |
| February 18, 2008 | NCT00617695 | Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents | Impax Laboratories, LLC | Phase 3 | Completed | Migraine | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00617695) |
| June 20, 2007 | NCT00488839 | IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis | Impax Laboratories, LLC | Phase 3 | Completed | Multiple Sclerosis | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00488839) |
| January 20, 2006 | NCT00279825 | Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease | Impax Laboratories, LLC | Phase 2 | Completed | Idiopathic Parkinson's Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00279825) |
| November 15, 2005 | NCT00253084 | Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's Disease | Impax Laboratories, LLC | Phase 2 | Completed | Parkinson's Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00253084) |
| October 17, 2005 | NCT00239564 | Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease | Impax Laboratories, LLC | Phase 1/2 | Completed | Idiopathic Parkinson's Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00239564) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 7 |
| Phase 3 | 10 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 13 |
| Migraine Disorders | 2 |
| Headache | 2 |
| Multiple Sclerosis | 2 |
| Muscle Spasticity | 2 |
| Pain | 1 |
| Restless Legs Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Laboratories in the United States](https://specstream.ai/data/businesses/laboratories/united-states)
- [Process servers in the United States](https://specstream.ai/data/businesses/process-servers/united-states)
- [Persian restaurants in the United States](https://specstream.ai/data/businesses/persian-restaurants/united-states)
- [Orthodontics practices in the United States](https://specstream.ai/data/businesses/orthodontics-practices/united-states)
- [Middle Eastern restaurants in the United States](https://specstream.ai/data/businesses/middle-eastern-restaurants/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
